On December 5, 2024, Nuvig Therapeutics, Inc. closed the transaction. The company has received its second and final tranche. The company has issued 153,523,410 series B preferred shares at issue price of $1.0487 per share for the gross proceeds of $161,000,000 in the transaction.

The transaction was co-led by new investors Sanofi Ventures, Blue Owl Healthcare Opportunities and NVP Associates, LLC and also included participation from new investors, B Capital Group Management, L.P., Leaps by Bayer, Global BioAccess Fund, LOTTE Corporation, Alexandria Venture Investments, LLC, a fund managed by abrdn Inc., returning investors Novo Holdings A/S, Bristol-Myers Squibb Company, Digitalis Ventures, Mission BioCapital, LP and Platanus. As a part of the transaction, Paulina Hill from Sanofi Ventures, Tim Anderson from Blue Owl Healthcare Opportunities and Tiba Aynechi from NVP Associates, LLC has joined the company's board of directors.